Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GT-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Centre for Neuropsychiatric Schizophrenia Research
Deal Size : Undisclosed
Deal Type : Collaboration
Gabather Partners with Danish Center to Conduct Phase 2 Study of GT-002 for Schizophrenia
Details : The collaboration aims to support the clinical advancement of GT-002, which is a small molecule GABAA receptor-positive allosteric Modulator. Currently, it is being evaluated for schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 04, 2024
Lead Product(s) : GT-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Centre for Neuropsychiatric Schizophrenia Research
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : GT-002
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gabather reports Initial Positive Results from the EEG/fMRI Target Engagement Study
Details : GT-002 is an oral small molecule GABAA receptor PAM eliciting both tonic and phasic inhibitory currents. It restores ketamine induced cognitive deficits in patients with schizophrenia.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : GT-002
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
